Ligand Pharmaceuticals
LGND
#4808
Rank
$1.24 B
Marketcap
$70.57
Share price
0.28%
Change (1 day)
-8.66%
Change (1 year)

P/E ratio for Ligand Pharmaceuticals (LGND)

P/E ratio as of April 2024 (TTM): 45.0

According to Ligand Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 45.0318. At the end of 2022 the company had a P/E ratio of -33.7.

P/E ratio history for Ligand Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-33.7-221.14%
202127.8-106.28%
2020-443-20949.58%
20192.13-83.05%
201812.5-91.19%
2017142-122.46%
2016-634-10933.9%
20155.85-89.6%
201456.3-3.98%
201358.6-100%
2012> 10001.2338542617679E+19%
201115.1-241.22%
2010-10.7-89.43%
2009-1016002.71%
2008-1.66-255.32%
20071.07-106.41%
2006-16.714.97%
2005-14.521.73%
2004-11.976.66%
2003-6.7450.86%
2002-4.47-70.8%
2001-15.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
10.4-76.96%๐Ÿ‡บ๐Ÿ‡ธ USA
13.7-69.69%๐Ÿ‡บ๐Ÿ‡ธ USA
135 199.62%๐Ÿ‡บ๐Ÿ‡ธ USA
19.1-57.63%๐Ÿ‡บ๐Ÿ‡ธ USA
7.85-82.58%๐Ÿ‡บ๐Ÿ‡ธ USA
72.0 59.92%๐Ÿ‡บ๐Ÿ‡ธ USA
11.3-74.89%๐Ÿ‡บ๐Ÿ‡ธ USA
11.8-73.88%๐Ÿ‡ฌ๐Ÿ‡ง UK
-2.86-106.35%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.